Latest Market News

McMillan Shakespeare Limited reported a 9.7% rise in statutory net profit for the first half of FY26, driven by strong revenue growth and productivity gains. The company declared a fully franked 62 cent dividend and announced a $10 million on-market share buyback.

thl reports an 11% rise in underlying NPAT for H1 FY26 and sets a bullish FY26 guidance, underpinned by strategic divestments and cost efficiencies.

Chorus Limited has reported a strong half-year performance driven by fibre broadband growth, operational efficiencies, and a return to profitability, while launching initiatives to boost digital inclusion.

Genesis Energy has reported a record first-half normalised EBITDAF of NZ$307 million, underpinned by strong hydro inflows and portfolio flexibility, while announcing a $400 million equity raise to accelerate its renewable growth strategy.

Fisher & Paykel Healthcare has raised its full-year revenue and profit forecasts for FY26, buoyed by strong hospital product growth and favourable exchange rates, while navigating the complexities of a recent US Supreme Court tariff ruling.

Perenti Limited reported steady half-year revenue of $1.73 billion with a 10.9% increase in net profit, underpinned by a $300 million Dalgaranga contract and growing drilling services in the US. The company also announced an unfranked interim dividend and a CEO transition underway.

Deal headlines and big drill hits shared the stage with a brutal sell-off in a handful of tiny raisings. The week’s biggest winners were backed by clear news; the biggest losers showed what happens when buyers vanish after a halt.

Big gains hit wealth platforms while Zip swung the other way as early optimism didn’t stick. Dividends and buy-backs kept coming, but investors still punished stocks where the next step looks unclear.

Small caps stole the spotlight, with a handful of stocks doubling on deal news and early-stage project updates. Large miners were steadier, but even they couldn’t fully escape the week’s sharp gap moves.

Two capital raisings and one brutal reset set the tone, even as several companies posted clean growth or strong clinical updates. Radiopharmaceuticals kept delivering good news, but investors still punished supply-chain and cash needs fast.

FortifAI’s funding and big claims around faster AI data processing drove the week’s loudest move, while two small caps jumped on price queries. Elsewhere, results season rewarded clear recurring revenue growth, but punished gaps where early buying didn’t stick.

Novatti Group has been served a writ in Malaysia over disputed earn-out payments from its 2022 ATX acquisition, with a claim of approximately AUD 2.67 million. Despite the legal challenge, ATX’s financial performance remains on an upward trajectory.